BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 27402913)

  • 1. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Wong DR; Coenen MJ; Derijks LJ; Vermeulen SH; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    Aliment Pharmacol Ther; 2017 Feb; 45(3):391-402. PubMed ID: 27943397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.
    Fangbin Z; Xiang G; Liang D; Hui L; Xueding W; Baili C; Huichang B; Yinglian X; Peng C; Lizi Z; Yanjun C; Feng X; Minhu C; Min H; Pinjin H
    Medicine (Baltimore); 2016 Apr; 95(15):e3326. PubMed ID: 27082580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.
    Chapdelaine A; Mansour AM; Troyanov Y; Williamson DR; Doré M
    Clin Rheumatol; 2017 Jun; 36(6):1341-1348. PubMed ID: 28130685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
    van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
    Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients.
    Liu Q; Wang Y; Mei Q; Han W; Hu J; Hu N
    Scand J Gastroenterol; 2016 Sep; 51(9):1093-9. PubMed ID: 27152547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
    Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM
    Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
    Ooi CY; Bohane TD; Lee D; Naidoo D; Day AS
    Aliment Pharmacol Ther; 2007 Apr; 25(8):941-7. PubMed ID: 17402998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).
    Odahara S; Uchiyama K; Kubota T; Ito Z; Takami S; Kobayashi H; Saito K; Koido S; Ohkusa T
    PLoS One; 2015; 10(9):e0137798. PubMed ID: 26360046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
    Angelberger S; Schaeffeler E; Teml A; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR; Schwab M; Reinisch W
    Inflamm Bowel Dis; 2013 Mar; 19(3):590-8. PubMed ID: 23388543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
    Nguyen TV; Vu DH; Nguyen TM; Lachaux A; Boulieu R
    Ther Drug Monit; 2013 Apr; 35(2):251-7. PubMed ID: 23503453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
    de Graaf P; de Boer NK; Wong DR; Karner S; Jharap B; Hooymans PM; Veldkamp AI; Mulder CJ; van Bodegraven AA; Schwab M
    Br J Pharmacol; 2010 Jul; 160(5):1083-91. PubMed ID: 20590602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.